Buy Like Buffett
Watchlist

VERTEX PHARMACEUTICALS INC / MA

VRTX · Healthcare · $121.2B mkt cap · FY2025 filings · · not refreshed in 35 days · Wide moat ·

On the watchlist

Wide moat
Share / Embed this score
Embed this score

The five investor questions

95

2021–2025 (latest 5 aligned FYs; v3 window cap 5): revenue $7.6B to $12.0B, increasing; diluted EPS 9.01 to 15.32, increasing.

100

Median gross margin 87.4% over 10y, very stable.

96

Median ROIC 35.6%, above the 12% hurdle in 89% of years.

73

Net debt/EBITDA n/ax, interest coverage 314x.

39

Owner earnings changed trend unclear over up to the ten most recent annual observations.

Price vs. value if growth stopped today

A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.

Above value if growth stopped todayBelow value if growth stopped today
228% above value if growth stopped today
$3.3B
$145.32
$235.43
$477.36
228% above value if growth stopped today

What today’s price assumes: owner earnings growing ~27%/yr over 5 years. The zero-growth estimate assumes owner earnings stay flat (0% growth).

How to read this

We solve for the constant annual change in owner earnings that would make the five-year zero-growth estimate equal today’s price. This keeps the existing model inputs and calculation unchanged; it is an expectations lens, not a forecast.

This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. The recent FY revenue series does not trigger the three-consecutive-declines flag.

Among the current top-score group, the median current price is 239% above the zero-growth estimate across 48 of the current top 50 companies by Moat Score with both values.

Score records captured Jul 26, 2026.

Exactly which 50 companies?

FTNT, META, MEDP, IBEX, MSFT, GOOGL, LULU, ANF, IDXX, TXRH, FHI, QLYS, FFIV, ADBE, LLY, MANH, VEEV, GRMN, SSD, MNST, DOCS, MCO, CPRT, NTAP, LRCX, NVDA, CORT, SFM, MPTI, ULTA, SN, RMD, ROL, PAYC, IRMD, INTU, DECK, MORN, LGCY, DAL, GWW, ISRG, MPWR, CTAS, LOPE, MRK, CMG, FAST, BKNG, ORLY

Missing a usable price or zero-growth estimate: ANF, BKNG.

Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 4% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.

19 years of fundamentals

The business, in plain English

VERTEX PHARMACEUTICALS INC / MA booked $12.0B of revenue in FY2025 in the Healthcare sector and kept 86.2% of it as gross profit — a high-margin business by that measure. After every other cost, 32.9% of each revenue dollar reached the bottom line.

Across the filed record, revenue grew from $176M (FY2008) to $12.0B (FY2025) — about 28.2% a year compounded over 17 years.

It earned 26.2% on invested capital in the latest filed year, FY2025. Across the full 16-year measurable filed record, median ROIC was 25.5%. Over the v3 recent window (9 measurable filed years), median ROIC was 35.6%. The Returns on Capital filter above scores it 96/100.

VRTX's latest filed year, FY2025, doesn't disclose total debt in a form the methodology can use, so current leverage is treated as unmeasured — never assumed to be zero.

Put together: Pricing Power is the strongest of the five filters (100/100) and Capital Allocation the weakest (39/100), which is how VRTX lands at 81/100 — a Wide moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

FY2007–FY2025 · 19 fiscal years, normalized from VRTX’s SEC filings

Sales, as filed$12.0B FY2025
$0$5B$10B2007201320192025
Revenue kept after cost of goods86.2% FY2025
0%50%100%2007201320192025
Standard ROIC or separately labeled Operating ROICROIC 26.2% FY2025
−200%0%2007201320192025
Cash an owner could take out$4.0B FY2025
$0$2B$4B2007201320192025

Gaps in a line mean that item isn’t in VRTX’s filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Flagship explainer

How VERTEX PHARMACEUTICALS INC / MA makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$12.0B · 100%Cost of revenue$1.7B · 14%Gross profit$10.3B · 86%Operating income$4.2B · 35%Income before tax$4.6B · 39%Income tax$690M · 6%Net income$4.0B · 33%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$12.0B100%
Cost of revenue$1.7B14%
$10.3B86%
$4.2B35%
Income before tax$4.6B39%
Income tax$690M6%
$4.0B33%
Source: · event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set
Embed this chart

Flagship explainer

What VERTEX PHARMACEUTICALS INC / MA owns — and owes

VERTEX PHARMACEUTICALS INC / MA's filing tags don't support a full breakdown — here's what is filed:

Table alternative
Filed lineValue% of assetsSource
Total assets$25.6B100%
Cash and equivalents$5.1B20%
Stockholders’ equity$18.7B73%
Source: · event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set

Flagship explainer

What drives VERTEX PHARMACEUTICALS INC / MA’s return on equity?

ROE is five filed business factors multiplied together.

DuPont return on equity factor treeReturn on equity branches into tax burden, interest burden, operating margin, asset turnover, and the equity multiplier.Return on equity23%Tax burden85%net income ÷ pretax incomeInterest burden111%pretax ÷ operating incomeOperating margin35%operating income ÷ revenueAsset turnover0.50×revenue ÷ average assetsEquity multiplier1.37×average assets ÷ average equityAs of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com
DuPont source inputs
InputValueFiscal yearSource
$4.0BFY2025
Income before tax$4.6BFY2025
Operating income$4.2BFY2025
$12.0BFY2025
Ending assets$25.6BFY2025
Beginning assets$22.5BFY2024
$18.7BFY2025
$16.4BFY2024
Source:
  • SEC filingFiling detailsAccession 0000875320-26-000056
· event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set
Embed this chart

Flagship explainer

Where VERTEX PHARMACEUTICALS INC / MA's cash went

VERTEX PHARMACEUTICALS INC / MA’s filing does not supply enough provenance-matched cash-flow lines for a truthful flow chart — here’s what is filed:

Table alternative
Filed lineValue% of cash from operationsSource
Cash from operations$3.6B100%
Depreciation and amortization$210M6%
Source: · event Dec 31, 2025 · retrieved Jul 26, 2026 · annual-row source set

Curated 19-manager tier

Who reported holding VERTEX PHARMACEUTICALS INC / MA

Delayed public 13F reports for 2026-Q2—not live positions, trades, or recommendations.

0 holding0 exited1 not holding1/19 resolved18 not retrieved

Named manager positions and quarter-over-quarter changes
ManagerReported positionQuarter-over-quarterFiling accession
Markel / Markel-GaynerNo position reportedNo position reported
Abrams CapitalNot retrievedComparison not retrievedFiling not retrieved
Akre CapitalNot retrievedComparison not retrievedFiling not retrieved
Baupost GroupNot retrievedComparison not retrievedFiling not retrieved
Berkshire HathawayNot retrievedComparison not retrievedFiling not retrieved
Brave Warrior AdvisorsNot retrievedComparison not retrievedFiling not retrieved
Dodge & CoxNot retrievedComparison not retrievedFiling not retrieved
First EagleNot retrievedComparison not retrievedFiling not retrieved
FundsmithNot retrievedComparison not retrievedFiling not retrieved
Gardner Russo & QuinnNot retrievedComparison not retrievedFiling not retrieved
Gates Foundation TrustNot retrievedComparison not retrievedFiling not retrieved
Mairs & PowerNot retrievedComparison not retrievedFiling not retrieved
Oakmark / Harris AssociatesNot retrievedComparison not retrievedFiling not retrieved
Pershing SquareNot retrievedComparison not retrievedFiling not retrieved
Polen CapitalNot retrievedComparison not retrievedFiling not retrieved
Sequoia / Ruane CunniffNot retrievedComparison not retrievedFiling not retrieved
Southeastern Asset ManagementNot retrievedComparison not retrievedFiling not retrieved
Tweedy, BrowneNot retrievedComparison not retrievedFiling not retrieved
Yacktman Asset ManagementNot retrievedComparison not retrievedFiling not retrieved

Position size uses shares and filed value from each manager’s 13F. Portfolio weight uses the eligible long-share filing denominator. Changes compare only with the immediately preceding calendar quarter.

Source: · event Jun 30, 2026 · retrieved Jul 26, 2026

Flagship explainer

What VERTEX PHARMACEUTICALS INC / MA insiders reported

Records still being gathered — partial as of retrieval Aug 30, 2026.

Partial coverage: the incomplete Form 4 walk cannot establish no activity, an activity date, or zero counts.

Moat Score history

16 logged readings since Jul 17, 2026 · append-only, never rewritten

Moat Score over timeLast scored reading of each day, on the 0–100 scale80.6 / 100
0406080100WideNarrowShallowNo moatJul 17, 2026Jul 26, 2026

Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.

Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars

  1. Normalizer upgraded unstamped (version unknown)moat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
  2. Methodology upgraded moat-index@2.0.0moat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
  3. Methodology upgraded moat-index@1.2.0moat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026

Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.

Insider activity

Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”

These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.

This machine-readable surface covers SEC ownership filings from 2003; it does not represent earlier paper-era records.

Records still being gathered — partial as of retrieval Aug 30, 2026.

Trailing-12-month totals and the 90-day cluster result are withheld because this issuer walk is incomplete.

No reported Form 4 rows were captured for VRTX; the incomplete walk cannot establish zero activity, zero counts, or a negative cluster result.

A filing source-event date will appear when a Form 4 row is captured.

Retrieved .

Track record

How VERTEX PHARMACEUTICALS INC / MA’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.

Point-in-time scores 2011–2025, one methodology version · reconstructed from filings on file each Dec 31 — never with hindsight

Point-in-time Moat Score (dot colored by tier)Indexed price (total-return (dividends reinvested))Rated Wide-moat that year

How to read this: each dot is what the engine would have scored VRTX on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.

0406080100WideNarrowShallowNo moatPoint-in-time Moat Score1002005001,000Indexed price · log scale (2012 = 100)201120142017202020232026

Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The price path is a total-return (dividends reinvested) index built from the same data the forward returns use; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.

What followed, in the years it rated Wide

In the 2 years VRTX rated Wide-moat (2023 and 2024), the median forward total return that followed — measured only after each year’s filings were public — was:

  • 1 year 5% vs the S&P 500’s 20% (price basis) · median over 2 years
  • 3 years None of the 2 years it rated Wide has a fully elapsed 3-year window with a benchmark to compare against yet.
  • 5 years None of the 2 years it rated Wide has a fully elapsed 5-year window with a benchmark to compare against yet.

These are medians computed from the data, not a claim about any one year. The company figures are total returns (dividends reinvested); the S&P 500 is the price-only ^GSPC index, which excludes dividends and so understates the index — the gap flatters the company. A quality rating is not a return forecast, and past returns don’t predict future ones. Educational only, not investment advice.

Healthcare context

#25 of 710 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

  1. #23REGN REGENERON PHARMACEUTICALS, INC.81.2Wide moat
  2. #24A AGILENT TECHNOLOGIES, INC.81.1Wide moat
  3. #26BTMD biote Corp.80.4Wide moat
  4. #27WAT Waters Corporation80.0Wide moat

Compare VRTX with its nearest peers →All Healthcare companies on the Index →

Common questions about VRTX

Does VERTEX PHARMACEUTICALS INC / MA have an economic moat?
Based on its FY2025 SEC filings, the Moat Index scores VERTEX PHARMACEUTICALS INC / MA (VRTX) 80.6 out of 100 — a Wide moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 95, pricing power 100, returns on capital 96, balance-sheet safety 73, capital allocation 39.
Is VRTX trading below the conservative owner-earnings estimate?
The value if growth stopped today — a zero-growth baseline — is $145.32 per share. It capitalizes normalized owner earnings at a 9% rate and assumes 0% growth. Versus a recent price of $477.36, that is 228% above value if growth stopped today. The model also publishes a capped-growth comparison, but the zero-growth estimate is the cautious baseline. It assumes trailing owner earnings persist and is unreliable for declining businesses. This is an educational estimate from primary SEC filings, not intrinsic value as a fact or investment advice.
How has VRTX's Moat Score changed over time?
The record logs 16 readings since Jul 17, 2026; the latest reads 80.6 out of 100 (wide moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell VRTX. See the disclaimer.